Stockreport

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sum...

Roivant Sciences Ltd.  (ROIV) 
PDF Sumitomo Pharma repurchase reduces shares outstanding by 9% In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg re [Read more]